The FDA has accepted for Priority Review the sBLA for aflibercept injection 8mg for the treatment of macular edema following RVO and for monthly dosing in approved indications.

A case presentation involving a patient with severe, symptomatic iliofemoral deep vein thrombosis and need for urgent ...

EYLEA HD is a treatment for retinal vein occlusion (RVO) that allows for dosing every 8 weeks after initial monthly doses, potentially halving injections. What is the FDA's action date for EYLEA ...

for aflibercept injection 8mg for the treatment of macular edema following retinal vein occlusion (RVO) and monthly dosing across all approved indications. The sBLA was supported by data from the ...

The sBLA seeks approval for Eylea HD to treat patients with macular edema following retinal vein occlusion (RVO), and for broadening the dosing schedule to include every 4-week (monthly) dosing across ...

The FDA's priority review of EYLEA HD targets macular edema post retinal vein occlusion and monthly dosing expansion. EYLEA HD's extended dosing intervals maintain efficacy, reducing treatment burden, ...

In the current issue of Circulation, Mehta and colleagues compared 1-year saphenous vein graft failure (defined as ≥75% angiographic stenosis or occlusion) and 5-year clinical events (composite of ...

Bayer seeks EMA approval to expand aflibercept 8 mg use for macular edema post retinal vein occlusion. Phase 3 QUASAR study data showed aflibercept 8 mg improved BCVA in patients with RVO, supporting ...

Aim: To describe the prevalence and risk factors of retinal vein occlusion (RVO) in an Asian population. Methods: The Singapore Malay Eye Study is a population-based, cross-sectional study of 3280 (78 ...

Patients taking serotonin reuptake inhibitors or statins show less susceptibility for retinal vein occlusions, and SRIs can add to statins’ preventive effect. Serotonin reuptake inhibitor use is ...

Faricimab can reduce the treatment burden in managing macular edema secondary to retinal vein occlusion. Faricimab has sustained efficacy, and can result in gains in best-corrected visual acuity (BCVA ...